Epigenetics: PTPRN2 / miR-153-3p / PHB2 Axis
1 Chalder et al. 2026 — PTPRN2 Hypomethylation and PHB2-miR-153-3p Axis in ME/CFS
Full Citation:: Chalder L, Elremaly W, Li D, Fang Y, Caraus I, Leveau C, Elbakry M, Franco A, Godbout C, Di Tomasso G, Nepotchatykh E, Rostami-Afshari B, Gimenez M, Moreau A. “PTPRN2 hypomethylation and PHB2-associated miR-153-3p maturation define dual epigenetic features linked to symptom variability in myalgic encephalomyelitis.” Journal of Translational Medicine. 2026. DOI:: 10.1186/s12967-026-08162-6 PMID:: not available at time of writing Study Design:: Cross-sectional EWAS; saliva DNA methylation (~850,000 CpG sites, Illumina EPIC array); n=54 ME/CFS vs 21 sedentary controls; University of Montreal group (Moreau). Key Findings::
- PTPRN2 hypomethylation identified and survives multiple-testing correction; enables patient subgrouping by epigenetic profile
- PTPRN2 hypomethylation associated with brain fog and cognitive difficulties
- Respiratory symptoms association in males only (sex-stratified subanalysis, exploratory)
- Reduced circulating miR-153-3p in patient blood; lower levels correlate with poorer delayed memory recognition
- PHB2 proposed to impair miR-153-3p maturation post-transcriptionally (cytoplasmic mechanism)
- Multi-level axis proposed: PTPRN2 epigenetic modification → reduced miR-153-3p (modulated by PHB2) → cognitive/respiratory symptomsConclusion:: First paper to link PTPRN2 hypomethylation to ME/CFS symptom variability, and to propose a PHB2-mediated post-transcriptional mechanism for reduced miR-153-3p as a secondary epigenetic feature. Provides a framework for patient subgrouping based on epigenetic profiles. Limitations:: Cross-sectional design (no causal proof); small n (54 vs 21); saliva proxy (not blood or brain tissue); sex-stratified subanalyses are exploratory; PHB2-miR-153-3p mechanism is a proposed model, not directly demonstrated in this study. Certainty:: 0.47